Funding

Adaptive Biotechnologies Raises $195M

92 Views

What does Adaptive Biotechnologies do?

Adaptive Biotechnologies, is a startup which offers research and diagnostic tools for clinicians and scientists involved in genomic immunology. It is a pioneer in the field of genomic immunology. Its main aim is developing next gen sequencing assays which characterize the adaptive immune system, which serves as a platform technology to the biopharmaceutical industry and the research community. immunoSEQ , is its flagship commercial product which used a proprietary immune profiling assay which analyzes B cells and T cells, which are important parts of the immune system’s defense against diseases, with specificity and depth.

Boosted by discoveries from immunoSEQ, Adaptive Biotechnologiesis at present developing a pipeline of clinical assays which are specific to the prognosis and diagnosis of cancer. All of this firm’s assays are combined with cloud computing infrastructure which simplifies the interpretation of huge quantities of data in an interface which is user friendly.

How much Adaptive Biotechnologies was funded?

Adaptive Biotechnologies raised $ 195 M in Series F round on May 7th from Matrix Capital, Tiger Management Corporation, Senator Investment Group and Rock Springs Capital.

Previous funding

  • $2.5M in Grant on September 13, 2013
  • $5M in Series C on April 7, 2014
  • $105M in Series D on April 15, 2014 from Viking Global Investors
  • $94M in Series E on January 7, 2015

What is next for Adaptive Biotechnologies?

The latest fund will be used to boost its significant expansion of its research platform and to support the commercialization of a target identification technology for T-cell therapy and for expediting its global regulatory submissions. Funds will also be used to supports in continuous growth of the largest adaptive immune receptors database in the world to inform therapeutic discoveries and future diagnostic discoveries across disease states.

More about Adaptive Biotechnologies

This immunosequencing platform was founded on January 1st, 2009 by Chad Robins, Christopher Carlson and Harlan Robins. It has its headquarters in Seattle, WA.

Related Posts